Advancing Research & Creating Synergy: Connecting Patients to Clinical Trials

We believe that **IMMEDIATE ACCESS** for patients with brain and other cancers where there is no effective standard treatment protocol, clinical trials offer the best HOPE for survival.

Yet, fewer than 10% of patients across all cancers enroll in clinical trials and therefore are effectively denied access to new and potentially life-extending and life-saving treatments.

For researchers, this means that promising new treatments take a lot longer and are much more expensive to bring to market than they would be otherwise.

All of this slows the process of science ...and in finding a cure (or cures) for this disease.

Making the Connection

If you are a brain cancer patient, caregiver, family member or friend, we are here to help you throughout your journey.

You can connect with us via phone, email, website portal, online support groups, Facebook, Skype, Twitter, and in person.

About the EndBrainCancer Initiative

The EndBrainCancer Initiative is dedicated to closing the GAP to advanced treatment and clinical trial participation, and to providing HOPE to brain tumor patients and their families nationally.

Our goal is to improve patient outcomes by extending lives, increasing survivorship, and improving Quality of Life for patients nationally through quickly connecting patients with our network of regional experts in Brain Tumor Treatment & Research across the U.S. and to the best and most advanced treatment options available via a personal consult or via social media and website.

Take Action & Learn from Social Media!

- Facebook.com/EndBrainCancer
- @EndBrainCancer
- Chris Elliott Fund Company Page

To help us triage your case, please visit the Patient Support page of our website and complete a Patient Inquiry Form, EndBrainCancer.org/we-can-help

You can also contact us via phone or email:

425.444.2215 | WeCare@EndBrainCancer.org
EndBrainCancer.org

Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the bio/life sciences industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of updating and improving NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

“Direct Connect” Center
16150 NE 85th St, #201
Redmond, WA 98052

A Guidestar Platinum Charity
www.guidestar.org/profile/26-2185614

This brochure provided by support from:

**Individual Supporters**

Donor-Advised Funds
Reshaping the Healthcare Delivery Process

- "Direct Connect" Program. IMMEDIATELY connecting brain tumor patients and their families to:
  - Innovative & advanced treatments including immunotherapies, vaccines, & medical devices
  - Genomic & proteomic profiling/molecular pathways and testing of tumor tissue
  - Top Neuro-Surgeons, Specialists and Principal Investigators across the U.S.
  - “Pre-qualifying” patients for Clinical Trials
  - Arranging for a 2nd, 3rd, or 4th opinion

- Pre-qualifying patients for advanced treatment or clinical trials, thereby reducing the cost & length of clinical trials for researchers and patients and providing opportunities for translational treatments to reach patients faster than current FDA practice.

- Improving Patient Outcomes through direct access to specialists and clinical trials: Brain tumors are the 2nd leading cause of cancer death in 19-year old and younger children. Very few adults survive Glioblastoma, the most common and deadly of brain cancers, with current Standard of Care.

- Changing the Conversation: So that patients and their families know to what to ask for, demand, and sign upon diagnosis and prior to surgery.

In 2002-2006, the money that the EndBrainCancer Initiative (EBCI, formerly the Chris Elliott Fund) raised enabled researchers to make a series of remarkable discoveries that helped to define and prioritize the genes in Glioblastoma. This led to the discovery that Glioblastoma Multiforme (GBM) is not 1 disease but subclasses of disease.

Now is the time to change NCCN guidelines to include saving of tumor tissue, genomic/molecular testing of the patient’s tumor tissue, and using these findings to inform the patient’s treatment plan. Partner with us.

Deliann Elliott Mydland
Founder & President
EndBrainCancer Initiative

Empowering Patients | Improving Outcomes

The EndBrainCancer Initiative provides direct connections to top specialists (including neuro‐surgeons, neuro‐oncologists & principal investigators) and education and guidance to patients and their families throughout their brain tumor journey, including easy‐to‐use Fact Sheets, workbooks and other tools.

We’ve demonstrated that IMMEDIATE ACCESS and connections to brain tumor specialists leads to advanced & innovative treatment, clinical trials, and critical care - this is how we extend and save lives while increasing Return on Investment.

Effecting Change

From the day it was founded in 2002, the EndBrainCancer Initiative has been dedicated to changing how brain cancer is treated and to offering HOPE to brain cancer patients and their families while advancing science.

- 2002-2007: provided the seed research money that led to the discovery that Glioblastoma Multiforme (GBM) is not 1 disease but subclasses of disease.
- Funded research that identified and prioritized the genes that cause GBM which inspired a multi-center effort across the U.S. to determine the alterations in all human cancers.
- Advocating on issues of national public health policy including FDA approval for new treatments, reimbursement for new treatment options and proper coding.
- 2015: launched the EndBrainCancer Initiative, a nation-wide collaborative of industry leaders, research scientists and leading physicians to change the clinical trial process and focus on immunotherapy, vaccines, Phase 0 studies and personalized medicine.
- 2017 and beyond: creating survivors through IMMEDIATE ACCESS and through changing the Standard of Care, NCCN guidelines, and practice.

U: 07-10-18